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Dysregulation of interleukin-6 has been reported to be
associated with various types of tumors, and interleu-
kin-6 plays an important part in regulating apoptosis
in many types of cells. Previously, Mcl-1 was shown to
be signi¢cantly increased in interleukin-6-overex-
pressed basal cell carcinoma cells and conferred on
them anti-apoptotic activity. The aim of this study was
to investigate which signaling pathway is involved in
the anti-apoptotic e¡ect of interleukin-6 on basal cell
carcinoma cells. Here we show that the addition of re-
combinant 100 ng per ml interleukin-6 to basal cell car-
cinoma cells induced a 2.3-fold increase in the level of
Mcl-1 protein in basal cell carcinoma cells. Transfection
with dominant-negative STAT3 (STAT3F) into inter-
leukin-6-treated basal cell carcinoma cells caused a de-
crease of phosphotyrosyl STAT3 but did not alter Mcl-1
protein levels; however, AG490, a Janus tyrosine kinase
inhibitor, was capable of inhibiting the interleukin-6-
induced elevation of Mcl-1 protein. Next, interleukin-6
stimulation elicited extracellular signal-regulated kinase
activation in basal cell carcinoma cells, and the mito-
gen-activated protein kinase inhibitor, PD98059, could
a¡ect this response without a¡ecting the interleukin-
6-medi-ated Mcl-1 upregulation. Use of the two phos-
photidyl inositol 3-kinase inhibitors, LY294002 and
wortmannin, to check whether this pathway is involved
in Mcl-1 upregulation by interleukin-6, we found
that the phosphotidyl inositol 3-kinase inhibitors
completely attenuated the interleukin-6-induced Mcl-1
upregulation. Furthermore, in the interleukin-6-over-
expressing basal cell carcinoma cell clone, dominant-
negative Akt also signi¢cantly reduced the increased
level of Mcl-1. Interestingly, Janus tyrosine kinase inhi-
bitor, AG490, treatment strongly blocked the phospho-
tidyl inositol 3-kinase pathway activation, as evidenced
by the decrease in phospho-Akt level. Blockage of
phosphotidyl inositol 3-kinase/Akt pathway abolished
the interleukin-6-mediated anti-apoptotic activity in
ultraviolet B treated cells. Unexpectedly, without ultra-
violet B irradiation, STAT3F transfection also induced a
signi¢cant apoptosis in basal cell carcinoma/interleu-
kin-6 cells. Taken together, our data suggest that both
the phosphotidyl inositol 3-kinase/Akt and STAT3
pathways are potentially involved in interleukin-6-
mediated cell survival activity in basal cell carcinoma
cells; however, the upregulation of the anti-apoptotic
Mcl-1 protein by interleukin-6 is mainly through the
Janus tyrosine kinase/phosphotidyl inositol 3-kinase/
Akt, but not the STAT3 pathway. Key words: Akt/anti-
apoptosis/basal cell carcinoma/interleukin-6/Mcl-1/phosphoti-
dyl inositol 3-kinase/STAT3/ultraviolet B. J Invest Dermatol
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nterleukin (IL)-6 is a multifunctional cytokine acting on
various types of cells. This cytokine was able to induce acute
phase plasma protein synthesis in hepatocytes (Gauldie et al,
1987) and to enhance the proliferation and/or di¡erentiation
of a wide array of cells (Hirano et al, 1986; Garman et al, 1987;
Van Damme et al, 1987; Lotz et al, 1988;Tosato et al, 1988; Grossman
et al, 1989; Gilhar et al, 1995). IL-6 has been implicated in the
pathogenesis of psoriasis (Yoshinaga et al, 1995; Ameglio et al,
1997), which is an idiopathic skin disease that is histopathologi-
cally characterized by accelerated epidermal pro-liferation, ab-
sence of apoptosis in epidermis, and in¢ltration of in£ammatory
cells. The IL-6 level is rapidly elevated in human keratinocytes
when exposed to ultraviolet (UV) irradiation (Petit-Frere et al,
1998); however, the role of IL-6 in skin cells in response to
UV remains unclear. An interesting study showed that IL-6 treat-
ment caused growth arrest in human primary melanoma cells
but failed to induce the same e¡ect in more aggressively growing
melanoma cells (Florenes et al, 1999). This indicates that IL-6 may
act as a negative regulator in the development of human melano-
ma. In contrast, it has been reported that IL-6 is a mitogen for
basal cell carcinoma (BCC) cells ( Jee et al, 2001). These ¢ndings
suggest that IL-6 may have di¡erent e¡ects on di¡erent types of
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skin cells and its e¡ects are certainly associated with the patho-
genesis of human skin cancer.
BCC is one of the most commonly encountered neoplasms in
the world and is characterized as locally aggressive with little
metastatic potential (Lear et al, 1998). UV irradiation is considered
to be a major etiologic factor for the pathogenesis of BCC (Kricker
et al, 1994). Interestingly, UV irradiation can trigger the release of
IL-6 and tumor necrosis factor-a from human epidermal kerati-
nocytes (Chung et al, 1996; Avalos-Diaz et al, 1999). Cultured BCC
cells stained with speci¢c cytokine antibodies showed signi¢cant
expression of IL-6 (Yen et al, 1996). These ¢ndings suggest the
possible involvement of IL-6 in the pathologic process of BCC.
To answer this question, a previous study has shown that ectopic
overexpression of IL-6 in BCC cells resulted in enhancement of
tumorigenicity in nude mice as compared with vector control
cells ( Jee et al, 2001). Besides, the IL-6-mediated enhancement of
tumor potency of BCC cells was at least in part due to its anti-
apoptotic activity ( Jee et al, 2001). The Mcl-1 gene has further
been identi¢ed as a critical downstream e¡ector of IL-6-elicited
anti-apoptotic signaling. Furthermore, IL-6 has recently been
shown to function as a key player in the apoptosis of several
human cancer cells, such as multiple myeloma, renal cell carcino-
ma, prostate cancer, Kaposi’s sarcoma, colorectal cancer, and hepa-
toma (Akira and Kishimoto, 1992; Aoyagi et al, 1996; Adler et al,
1999; Aoki et al, 1999; Kinoshita et al, 1999; Kuo et al, 2001).
This step in the mechanism of deregulation of apoptosis has
emerged as a central feature in human cancer development
(Hanahan and Weinberg, 2000). The cell survival signaling
pathways elicited by IL-6 have been investigated but mostly in
hematopoietic cells. In general, three major signaling pathways,
including the STAT3 pathway (Puthier et al, 1999), phosphotidyl
inositol 3-kinase (PI 3-kinase)/Akt pathway (Qiu et al, 1998;
Chen et al, 1999; Kuo et al, 2001; Wei et al, 2001), and mitogen-
activated protein kinase pathway (Thabard et al, 2001) have been
reported to be involved in the IL-6-mediated cellular functions.
Which signaling pathway is active after IL-6 treatment depends
upon the cell context. In this study, we sought to determine the
role of IL-6 in UVB-induced apoptosis in BCC cells and identify
which signal transduction mediators would be involved in IL-6-
induced Mcl-1 expression.
MATERIALS AND METHODS
Cell origin and cell culture The BCC cell line originally named
BCC-1/KMC was established from human BCC derived from the
undi¡erentiated type of BCC tumor arising on a thermal traumatic scar.
Cytokeratin K8.13 was demonstrated in the cytoplasm (Yen et al, 1996).
The BCC cell line was cultured in RPMI-1640 medium supplemented
with 10% fetal bovine serum, streptomycin (100 mg per liter), and
penicillin (60 mg per liter). The vector clone (BCC/neo) and IL-6
overexpression clone (BCC/IL-6) were cultured in the same medium as
described above, but with the addition of 500 mg G418 per ml (Jee et al,
2001).
Antibodies and reagents A⁄nity-puri¢ed monoclonal mouse anti-
Akt, anti-Mcl-1, anti-ERK1/2, and anti-phospho-ERK1/2 antibodies,
and rabbit polyclonal anti-IL-6Ra IgG were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The anti-phospho-Akt was
from Promega (Madison, WI). The anti-phospho-STAT3 was from Up-
state Biotechnology (Lake Placid, NY). The PI 3-kinase inhibitors
wortmannin (WM), LY294002 (LY), Janus tyrosine kinase ( JAK)
inhibitor, AG490 and MEK inhibitor, PD98059 were obtained from
Calbiochem (San Diego, CA).
Western blot analysis The cellular lysates were prepared as described
previously (Kuo et al, 1998). A 50 mg sample of each lysate was subjected
to electrophoresis on 10% sodium dodecyl sulfate^polyacrylamide gels,
and for detection of Mcl-1, STAT3, phospho-STAT3 (p-STAT3), Akt,
phospho-Akt (p-Akt), ERK1/2, and phospho-ERK1/2 (p-ERK1/2). The
samples were then electroblotted on nitrocellulose paper. After blocking,
blots were incubated with anti-Mcl-1, anti-STAT3, anti-p-STAT3,
anti-Akt, anti-p-Akt, anti-ERK1/2, and anti-p-ERK1/2 antibodies in phosphate-
bu¡ered saline (PBS) containing Triton X-100) for 1 h followed by three
washes (15 min each) in PBS Triton X-100, and then incubated with
horseradish peroxidase-conjugated goat anti-mouse IgG (for the primary
monoclonal antibodies) and with horseradish peroxidase-conjugated goat
anti-rabbit IgG (for the primary polyclonal antibodies; Amersham),
respectively, for 30 min. After washing, blots were incubated for 1 min
with the western blotting reagent ECL (Amersham (Buckinghamshire,
UK)) and chemi-luminescence from the blots was detected by exposure
of Kodak-BioMax ¢lms to the blots for 30 s to 10 min. The intensity of
bands on auto-radiograms were quanti¢ed by scanning laser densitometry.
Reverse transcriptase^polymerase chain reaction (reverse trans-
criptase^PCR) RNA from BCC cells treated with IL-6 were isolated
using commercial kits (BIOTECX Laboratory Inc. (Houston, TX)). The
total RNA was subjected to ¢rst-strand synthesis using Random
Hexamer (Amersham, Pharmacia Biotec (Buckinghamshire, UK)) and
M-MLV Reverse Transcriptase (RNase H Minus) (Promega) at 371C for
3 h. The cDNAwas then diluted to a ¢nal volume of 50 ml and quanti¢ed.
Five micrograms of cDNA was ampli¢ed in the presence of 0.5 U Taq
polymerase per ml (Protech Technology, Taipei, Taiwan) and 25 pmol of
both the sense and the anti-sense Mcl-1 or b-actin oligonucleotides in
PCR bu¡er (10 mM Tris pH 9, 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin,
and 0.1% Triton X-100):
MCl-1 sense, 50 -GCGGATCCACCATGTTTGGCCTCAAAAGA-30
MCl-1 anti-sense, 50 -GCGTCGACAGGCTATCTTATTAGATATGC-30
b-actin sense, 50 -CGTCTGGACCTGGCTGGCCGGGACC-30
b-actin anti-sense, 50 -CTAGAAGCATTTGCGGTGGACGATG-30
The reaction mixture was incubated for 5 min at 941C and then ampli¢ed
by 25 PCR cycles (denaturation for 1 min at 941C, annealing for 1 min at
551C for Mcl-1 and 561C for b-actin, and extension for 1 min at 721C).
Each PCR product was then analyzed on a 2% agarose gel, stained with
1 mg ethidium bromide per ml, viewed and photographed. The intensity of
bands on photographs was quanti¢ed by scanning laser densitometry.
DNA construct and transient transfection To construct a
hemagglutinin epitope-tagged dominant-negative mutant of an Akt
(dnAkt) expression plasmid, an hemagglutinin epitope tag was inserted
into dnAKT cDNA and cloned into a pcDNA3 vector (GIBCO,
Invitrogen; Grand Island, NY; Chen et al, 1999). IL-6-overexpressing BCC
cells (BCC/IL-6) were plated 24 h before transfection at a density of 1105
cells in 35 mm Petri dish. Cells were transfected with 1 mg of dnAkt
plasmid using, according to the manufacturer’s instructions, the
TransfastTM Transfection Reagent (Promega). For assay of JAK/STAT3
signal pathway, 1 mg of the hemagglutinin-tagged dominant-negative
mutant of STAT3F plasmid (Nakajima et al, 1996) or control plasmid
(pcDNA3) was constructed using the same method described above. The
amount of hemagglutinin was concomitantly measured to con¢rm the
transfection e⁄ciency.
Flow cytometry for apoptosis assay Cell cultures grown to about 70^
80% con£uence and serum-starved for 24 h were irradiated with UVB at
25 mJ per cm2. Twenty-four hours later, the £oating cells were collected
from culture medium, centrifuged, and then washed once with PBS.
Cells that adhered to the culture dish were trypsinized with 0.5 ml of
trypsin (0.05% trypsin and 0.02% ethylenediamine tetraacetic acid) for 5
min and then collected. The £oating cells and the collected adherent cells
were pooled and centrifuged at 1500 g for 5 min. Pellets were washed
with PBS twice, followed by adding 200 ml of PBS and 800 ml of
absolute ethanol (i.e., 80% EtOH) and incubated at 201C for at least 3
h. Then, 0.5% Triton X-100 (in PBS) was added and mixed well,
followed by RNase (¢nal volume 0.05% v/v), and the mixture was
incubated at 371C for 20^30 min. An equal volume of propidium iodide
(50 mg per ml in PBS) was added to the samples, which were then
analyzed by £ow cytometry (FACSCalibur, Becton Dickinson, Le Pont
de Claix, France) using CELLQuest software (Becton Dickinson).
RESULTS
IL-6 upregulates Mcl-1 in human BCC cells Previous data
demonstrated that the Mcl-1 protein level, but not other Bcl-2
family members, was obviously increased in BCC/IL-6 ( Jee et al,
2001). Here we show that exposure to human recombinant IL-6
also increased the Mcl-1 protein level in BCC cells. Western
blotting revealed that upon IL-6 stimulation with a dose of
100 ng per ml, the level of Mcl-1 protein initially increased at
2 h, and peaked at 6^8 h, then declined to basal level (Fig 1A).
In contrast, the level of Bcl-2 protein was little changed
(Fig 1A). A 2.3-fold increase of Mcl-1 protein occurred in BCC
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cells after exposure to 100 ng per ml, respectively.We previously
reported that the BCC/IL-6 cells displayed an elevated level of
Mcl-1 (Jee et al, 2001). Here we found that the increased level of
Mcl-1 in BCC/IL-6 cells was e¡ectively diminished by treatment
with speci¢c anti-IL-6Ra antibody but not by control IgG
(Fig 1B). The above ¢ndings suggest that both paracrine and
autocrine IL-6 can induce endogenous Mcl-1 upregulation in
BCC cells. In addition, reverse transcriptase^PCR analysis
showed that mcl-1mRNAwas signi¢cantly elevated and peaked
at 6^8 h after IL-6 treatment (Fig 1C), suggesting that the IL-6-
mediated increased in mcl-1 gene expression is possibly through
transcriptional regulation.
STAT3 and ERK1/2 activation are not required for
Mcl-1 upregulation mediated by IL-6 Determining which
signaling pathways are involved in IL-6-mediated Mcl-1
upregulation in human BCC cells was the next topic of interest.
First, possible involvement of the STAT3 pathway in IL-
6-mediated Mcl-1 upregulation was examined. To address
this issue, either control vector or STAT3 dominant-negative
mutant (STAT3F), in which Tyr-705, a phosphoacceptor site
of STAT3, was mutated to phenylalanine (Nakajima et al, 1996),
was transiently transfected into BCC/IL-6 cells. Transient trans-
fectants and pcDNA3 control cells were analyzed for their e¡ect
on STAT3 activity by determining the tyrosine-phosphorylation
status of STAT3 (p-STAT3) in the IL-6 overexpressing BCC cells.
Figure1. IL-6 regulates the expression of Mcl-1 in human BCC
cells in a time-dependent manner. (a) Twenty-four hour serum-starved
BCC cells (5105 per ml) were treated with 50 ng per ml or 100 ng per ml
of IL-6 for di¡erent amounts of time (0, 2, 4, 6, 8, or 16 h). (b) Serum-
starved BCC cells (5105 per ml) were treated 1 mg of anti-IL-6Ra anti-
body for 12 h. After treatment, cell lysates were prepared and analyzed by
western blotting as described in Materials and Methods. (c) The number be-
low each lane indicate the relative intensity to control (de¢ned as 1.0). This
is one representative experiment of three.
Figure 2. STAT3 pathway and ERK pathway are not involved in IL-6 upregulation of Mcl-1. (a) Dominant-negative STAT3 (dnSTAT3, STAT3F)
reduces IL-6-induced tyrosine phosphorylation of STAT3. After transient transfection of BCC/IL-6 with control vector (pcDNA3) and hemagglutinin-
tagged dominant-negative STAT3 (STAT3F) for 48 h, the cell lysates with an equal amount of proteins were subjected to western blotting with anti-phos-
pho-STAT3 antibody, which speci¢cally recognizes the phosphotyrosine at Tyr 705 of the STAT3 protein, was performed to check their STAT3 function.
Dominant-negative STAT3 failed to inhibit IL-6-induced Mcl-1 expression. Lysates from cells (as indicated above) were analyzed by western blotting using
anti-Mcl-1 antibody. (b,c) JAK inhibitors (AG490) reduced IL-6-induced tyrosine phosphorylation of STAT3 and serine phosphorylation of Akt and Mcl-1
expression; MEK inhibitor (PD98059) abolished the IL-6-induced activation of ERK, but not Mcl-1 expression. Forty-eight hour serum-starved BCC cells
(5105 per ml) pretreated with IL-6 (100 ng per ml) for 15 min were then incubated with 25 mM and 50 mM of AG490 for a further 1 h. Lysates from cells as
indicated were used for western blotting with anti-phospho-STAT3 antibody (c, lower panel) and anti-phospho-Akt antibody (c, lower panel). For assessment
of Mcl-1, the incubation time of AG490 was 6 h. Lysates were used for western blotting with anti-Mcl-1 antibody (b). To investigate the involvement of
RAS/MEK/ERK pathway, serum-starved BCC cells (5105 per ml) pretreated with IL-6 (100 ng per ml) for 15 min were incubated with 25 mM and 50 mM
of PD98059 for a further 1 and 6 h for assessment of ERK1/2 (c, upper panel) and Mcl-1, respectively (b). Cell lysates were prepared and used for western
blotting with antibody speci¢c to phosphorylated ERK1/2 (c, upper panel) or anti-Mcl-1 antibody (b). The number below each lane indicate the relative
intensity to control (de¢ned as 1.0). This is one representative experiment of three.
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Expression of STAT3F resulted in inhibition of STAT3 function,
as evidenced by the decrease in p-STAT3 with addition of a
speci¢c anti-p-STAT3 antibody (Fig 2A); however, Mcl-1 and
other internal control proteins such as Bcl-2 and a-tubulin,
were all not signi¢cantly attenuated by transfection with
STAT3F. The high expression of hemagglutinin and marked
decrease of p-STAT3 after transfection of hemagglutinin-tagged
STAT3F indicated that a high transfection e⁄ciency was achieved
and allowed for detecting the inhibitory e¡ect of STAT3F on the
level of Mcl-1 (Fig 2A). To con¢rm further that the JAK, an
upstream kinase of STAT3, is not involved in the IL-6-induced
Mcl-1 upregulation, a speci¢c inhibitor for the JAK family of
kinases, the tyrphostin AG490, was utilized. As Fig 2(B)
illustrates, pretreating BCC cells with AG490 signi¢cantly
reduced the tyrosine-phosphorylated state of STAT3 and Mcl-1
in the presence of IL-6, suggesting that JAK is necessary
for Mcl-1 expression induced by IL-6; however, according to
Fig 2(A), activation of STAT3 pathway is not required for IL-6-
induced Mcl-1 upregulation. Therefore, we strongly suggest
that JAK induces Mcl-1, possibly through another downstream
mediator.
Next, we examined whether ERK1/2 could be activated by
IL-6 and be involved in Mcl-1 upregulation in this cell context.
Figure 2(C) shows that IL-6 apparently activated the ERK
pathway in BCC cells, as evidenced by the increased phos-
phorylated form of p42 and p44. The IL-6-induced increase
of phosphorylated ERK, as expected, was greatly reduced by
treatment with PD98059, a highly speci¢c inhibitor of MEK;
however, PD98059 failed to inhibit the IL-6-induced Mcl-1
expression. These ¢ndings indicate that in BCC cells, the ERK
pathway is not involved in IL-6-induced Mcl-1 upregulation.
The PI 3-kinase/Akt pathway is involved in the IL-
6-induced Mcl-1 expression Previous investigations on
di¡erent cell modes have demonstrated that IL-6 could activate
PI 3-kinase and Akt pathways, which mediate the anti-apoptotic
signal of IL-6 in human hepatoma Hep3B cells (Chen et al, 1999;
Kuo et al, 2001) and human cervical cancer C33A cells (Wei et al,
2001). We thus examined whether PI 3-kinase/Akt pathway is
involved in IL-6-induced Mcl-1 upregulation in BCC cells. To
address this, two speci¢c inhibitors of PI 3-kinase,WM and LY,
were used. As Fig 3(A) reveals, 12.5 or 25 mM of LY or 50 or
100 nM of WM signi¢cantly decreased the elevated level of
Mcl-1 induced by IL-6. Under identical circumstances, IL-6-
stimulated PI 3-kinase activity was blocked by both LY and
WM, as indicated by the decrease of the phosphorylated form of
the Akt protein (p-Akt), which was recognized by a speci¢c
antibody (Fig 3B). The serine/threonine protein kinase Akt is a
downstream e¡ector of PI 3-kinase and can be activated by IL-6
in Hep3B cells (Chen et al, 1999; Kuo et al, 2001) and C33A cells
(Wei et al, 2001). To assess the role of Akt in the IL-6-induced
Mcl-1 increase in BCC cells, the e¡ect of dnAkt was
investigated. A hemagglutinin-tagged kinase-defective dnAkt
(Chen et al, 1999) was transiently transfected into BCC/IL-6 cells
herein to examine its in£uence on IL-6-mediated Mcl-1
upregulation. Figure 3(C) reveals that the increased Mcl-1
protein level in BCC/IL-6 cells was signi¢cantly diminished by
transfection with dnAkt but not with pcDNA3 control vector.
The successful expression of dnAkt in BCC/IL-6 cells was
determined by the hemagglutinin level using western blotting
(Fig 3C). Above ¢ndings indicate that PI 3-kinase and its
downstream Akt are activated by IL-6 and mediate the signaling
to upregulate the level of Mcl-1.
In Fig 2(B), we have clearly demonstrated that JAK is critical
for IL-6-mediated Mcl-1 upregulation. Besides, it is known that
JAK is recruited immediately by gp130 upon IL-6 treatment
(Puthier et al, 1999).We thus propose that JAK may act upstream
to transduce signaling to PI 3-kinase/Akt pathway and ¢nally
activate the Mcl-1 expression. To clarify this hypothesis, we
checked whether AG490 treatment would a¡ect the level of p-
Akt in BCC cells treated with IL-6. Figure 3(D) shows that the
IL-6-induced increase in phosphorylated Akt levels in BCC cells
was markedly diminished by 25 and 50 mM of AG490. These data
suggest that the signaling pathway responsible for IL-6 mediation
Figure 3. PI 3-kinase/Akt pathways are involved in the IL-6 upregulation of Mcl-1. (a) PI 3-kinase inhibitors reduced IL-6-induced Mcl-1 expres-
sion. Twenty-four hour serum-starved BCC cells (5105 per ml) were pretreated with IL-6 (100 ng per ml) for 15 min followed by incubation with PI 3-
kinase inhibitors, LY (12.5 and 25 mM) or WM (50 and 100 nM) for six more hours. The cell lysates with an equal amount of protein were subjected to
western blotting with anti-Mcl-1 antibody. (b) PI 3-kinase inhibitors attenuated IL-6 elicited serine phosphorylation of Akt. The cells were treated (as
indicated above), except incubation time with IL-6 was for 1 h. Anti-pAkt antibody was used for western blotting analysis. (c) dnAkt inhibits IL-6-regu-
lated Mcl-1 upregulation. BCC/IL-6 cells were transfected with hemagglutinin-tagged dnAkt or control vector (pcDNA3) for 48 h. Cell lysates were
analyzed by western blotting using anti-Mcl-1 antibody (upper panel) and anti-hemagglutinin antibody (lower panel). (d) AG490 attenuates activation of
Akt in a concentration-dependent manner. The cells were treated as (b), except AG490 (25 and 50 mM) was used instead of LYandWM.The number below
each lane indicate the relative intensity to control (de¢ned as 1.0). This is one representative experiment of three.
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of Mcl-1 upregulation in human BCC cells may be a novel JAK/
PI 3-kinase/Akt pathway.
PI 3-kinase/Akt and STAT3 pathways are involved in the
anti-apoptotic activity of IL-6 It has previously been
demonstrated that IL-6-upregulated Mcl-1 confers resistance to
UVB-induced apoptosis in BCC cells, as evidenced by transient
transfection of anti-sense Mcl-1 (Jee et al, 2001). In this study, we
further demonstrated that the PI 3-kinase/Akt, but not STAT3,
pathway is critically involved in IL-6-mediated upregulation of
Mcl-1 in BCC cells. We thus examined whether PI 3-kinase/
Akt is involved in IL-6-regulated anti-apoptotic activity against
UVB irradiation. Exposure of BCC cells with recombinant
IL-6 resulted in a protection against UVB-induced apoptosis
(Student’s t test, p o 0.001, Fig 4A). The IL-6-mediated anti-
apoptotic activity against UVB was diminished by treatment
with LY or WM (Fig 4A). Supportive of this ¢nding,
transfection of dnAkt vector into BCC/IL-6 cells also lead to a
dramatic attenuation of their anti-apoptotic activity against
UVB irradiation (Fig 4B). These results strongly suggest an
important role of the PI 3-kinase/Akt signaling pathway in
IL-6-mediated cell survival. On the other hand, a previous
study showed that the STAT3 signaling pathway also contributes
the anti-apoptotic activity of IL-6 in human hepatoma cells
(Chen et al, 1999). Thus we transfected dominant-negative
STAT3 (STAT3F) into BCC/IL-6 cells to see its e¡ect on cell
death. Interestingly, STAT3F transfection caused a signi¢cant
increase of apoptotic cell death in BCC/IL-6 cells with or with-
out concomitant treatment with UVB, when compared with
control vector (Fig 4C). This observation suggests that STAT3
pathway was involved in IL-6-induced cell survival activity but
not in Mcl-1 upregulation. It is possible that activation of STAT3
and PI 3-kinase/Akt pathways may lead to di¡erent downstream
e¡ectors to protect cell death.
Taken together, our ¢ndings suggest that the anti-apoptotic
activity of IL-6 against UVB irradiation is mediated though the
activation of PI 3-kinase/Akt followed by upregulation of Mcl-1
in BCC cells. Without apoptotic stimuli, however, the STAT3
pathway provides a fundamental survival mechanism of IL-6
and this mechanism is independent of Mcl-1 upregulation.
DISCUSSION
IL-6 has been reported to be associated with various types of
tumors. Emerging evidence has demonstrated that IL-6 plays an
important part in regulating apoptosis in many types of cells.
This anti-apoptotic e¡ect may be attributed to the malignant
progression of tumors. UVB has been the important etiologic
factor of skin cancer. Nucleotide excision repair, apoptosis, and
cell cycle regulation are major defense mechanisms against the
carcinogenic e¡ect of UVB; however, the anti-apoptotic e¡ect
of UVB mediated by IL-6 in skin cells has not been well
documented.
We previously demonstrated that ectopic expression of IL-6 in
BCC cells resulted in an increment in Mcl-1 protein level ( Jee
et al, 2001). Here we show addition of recombinant IL-6 also evi-
dently elevates the level of Mcl-1 protein. These ¢ndings indicate
either an autocrine or paracrine loop of IL-6 synthesis can stimu-
late endogenous Mcl-1 expression in BCC cells. (Yang et al, 1996)
reported that unlike Bcl-2, Mcl-1 contains a PEST sequence;
Rogers et al (1986) found the amino acid sequences of ten proteins
with intracellular half-lives less than 2 hours contain one or
more regions rich in proline (P) glutamic acid (E), serine (S) and
threonine (T). They renamed these regions PEST regions. This
probably accounts for the lability of Mcl-1 (half-life of 1^3 h).
In a previous study using a hepatoma cell model, we observed
this same property of Mcl-1 protein (Kuo et al, 2001); however,
Figure 4. (a,b) PI 3-kinase/Akt and (c) STAT3 are involved in anti-apoptotic activity regulated by IL-6. (a) PI 3-kinase inhibitors blocked the
anti-apoptotic activity of IL-6. Serum-starved BCC cells (5105 per ml) were pretreated with PI 3-kinase inhibitors, LY (25 and 50 mM) orWM (50 and
100 nM), followed by IL-6 (100 ng per ml) for an additional hour. Cells were then irradiated with 25 mJ per cm2 of UVB. Twenty-four hours after UVB
irradiation, the cells were harvested for £ow cytometric analysis. (b) dnAkt blocks the anti-apoptotic e¡ect of IL-6. Forty-eight hours after transient trans-
fection of BCC/IL-6 with control vector (pcDNA3) and hemagglutinin-tagged dnAkt, BCC/IL-6 cells (5105 per ml) were irradiated with 25 mJ per cm2
of UVB or not irradiated. Twenty-four hours after UVB irradiation or no irradiation, cells were harvested for £ow cytometric analysis. (c) Dominant-
negative STAT3 (STAT3F) blocks the anti-apoptotic e¡ect of IL-6. Control vector (pcDNA3) and hemagglutinin-tagged dominant-negative STAT3
(STAT3F) were transiently transfected into BCC/IL-6 cells followed by the same procedure as (b). Parental BCC cells plus and minus UV served as controls
in (b) and (c). Percentages of hypodiploid cells are expressed as mean7SD of three experiments. Student’s t test was used for comparison.
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in this study, upon IL-6 stimulation, the level of Mcl-1 reached a
maximum at 6 h and was sustained for 16 h. It seems that
Mcl-1 has a longer half-life in BCC cells. The reason for the more
delayed induction and more prolonged half-life of Mcl-1 in BCC
cells is unknown and needs to be further investigated.
The signaling pathways leading to the Mcl-1 expression have
been investigated and varied according to the type of cell models
or stimuli employed. For example, activation of protein kinase
C/ERK pathway was necessary forTPA (12-o-tetradecanoylphor-
bol-13-acetate) or the microtubule-disrupting agent-induced
Mcl-1 expression in ML-1 human myeloblastic leukemia cells
(Townsend et al, 1998). IL-6 has been reported to induce Mcl-1
expression in multiple myeloma cells through the JAK/STAT3
pathway, but not the Ras/ERK pathway (Puthier et al, 1999). A
previous study showed that granulocyte-macrophage colony-sti-
mulating factor and IL-3 activated Mcl-1 expression in TF-1 leu-
kemia and Ba/F3 pro-B cells, respectively, and the Mcl-1
induction in both cells was mediated through the PI 3-kinase/
Akt pathway (Wang et al, 1999). The above investigations have
almost focused on the cell systems that are of hematopoietic
origin. Recently, we and others began to study the regulatory
mechanism of Mcl-1 by IL-6 in cells of epithelial origin. Interest-
ingly, unlike the situation in the hematopoietic cells, the PI 3-ki-
nase pathway is commonly activated and necessary for Mcl-1
upregulation in a wide array of epithelial cancer cells, including
hepatoma cells (Kuo et al, 2001), prostatic cancer cells (Chung et al,
2000), and cervical cancer cells (Wei et al, 2001). In agreement
with those who experimented in these cancer cell lines, we also
¢nd that the PI 3-kinase and its downstream e¡ector Akt is acti-
vated by IL-6 in BCC cells. The PI 3-kinase/Akt signaling path-
way is important for cell survival activity and Mcl-1 expression in
BCC cells.
Upon IL-6 binding, its receptor triggers the recruitment of
the signal-transducing protein gp130, subsequently leading to
the activation of the gp130-associated Janus kinases (JAK)
(Murakami et al, 1993; Lutticken et al, 1994; Narazaki et al, 1994).
JAK phosphorylate gp130 at several tyrosine residues and these
phosphotyrosines recruit various SH2 domain-containing pro-
teins, such as STAT and SHP-2 (Akira et al, 1994; Boulton et al,
1994). These events led to the activation of multiple signal trans-
duction pathways, such as the STAT, Ras/ERK and PI 3-kinase
pathway (Hibi et al, 1996; Heinrich et al, 1998). Although the
STAT3 pathway was not involved in IL-6-induced Mcl-1 upregu-
lation, blockage of the STAT3 pathway leads to cell death in IL-6-
overexpressed BCC cells. This indicates that certain anti-apoptotic
genes located downstream of the STAT3 pathway in IL-6-overex-
pressed BCC cells have not been identi¢ed yet. Consistently, the
STAT3 pathway has already been reported to participate in anti-
apoptosis of multiple myeloma cells (Fukada et al, 1996; Catlett-
Falcone et al, 1999). Bcl-xL was found to be elevated in human
multiple myeloma cells by IL-6 through the STAT3 pathway
(Puthier et al, 1999); however, a previous study showed that the
level of many Bcl-2 family proteins, including Bcl-xL and Bcl-2
was not altered in IL-6-overexpressed BCC cells (Jee et al, 2001).
This result excludes the possible involvement of some well-known
Bcl-2 family proteins in the STAT3 pathway-mediated anti-apop-
totic activity in IL-6-overexpressed BCC cells. Bellido et al (1998)
demonstrated that p21 is a downstream e¡ector of gp130/stat3 acti-
vation and a critical mediator of the pro-di¡erentiating and anti-
apoptotic e¡ects of IL-6 type cytokines on human osteoblastic
cells. In our system, increased expression of p21 protein was ob-
served upon IL-6 stimulation (data not shown). How p21 pro-
motes survival and any other anti-apoptotic factors regulated by
STAT3 remains elusive and requires further investigation.
The PI 3-kinase/Akt signaling pathway is involved in the sur-
vival e¡ect of many growth factors and some transforming onco-
genes (Skorski et al, 1997; Songyang et al, 1997). Recent ¢ndings
demonstrate that the pro-apoptotic protein Bad (Datta et al, 1997)
and procaspase 9 (Cardone et al, 1998) were the downstream tar-
gets of Akt, which protects cells from apoptosis; however, Bad
has a restricted tissue distribution, and not every survival signal
that activates Akt stimulates Bad phosphorylation (Scheid and
Durono, 1998). The phosphorylation inactivation of procaspase 9
byAkt is not generally observed in all cell types. It is possible that
Akt may exert its anti-apoptotic e¡ect via the activation or inac-
tivation of other cellular targets. Our studies in hepatoma cells,
cervical cancer cells, and BCC cells provide evidence that Mcl-1,
the survival factor activated by IL-6, is another cellular target of
the PI 3-kinase/Akt signaling pathway. Unlike the phosphoryla-
tion of Bad or procaspase 9, the PI 3-kinase/Akt pathway upregu-
lates the Mcl-1 expression at the level of transcription (data not
shown).
Although IL-6 exerts an anti-apoptotic activity in a wide vari-
ety of cells, the cell survival signaling pathways activated by the
cytokine is varied. Greater understanding of the speci¢c anti-
apoptotic signal pathways activated by IL-6 in skin cancer cells
may enable the development of e¡ective preventive measures or
therapies for human skin cancers.
This work was supported by grants from National Science Council,Taiwan (NSC-
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